Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research

{
  "signal_id": "9ba868b5-873e-95c3-366b-9bb969081daf",
  "signal_type": "news",
  "signal_subtype": "signs_new_client",
  "detected_at": "2026-10-23T14:57:21+00:00",
  "company": {
    "name": "Tempus AI",
    "domain": "tempus.com"
  },
  "data": {
    "url": "https://www.marketscreener.com/news/pathos-ai-partners-with-bristol-myers-squibb-and-tempus-ai-to-accelerate-medical-research-ce785cdfda8bf526",
    "title": "Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research - marketscreener.com",
    "excerpt": "Pathos AI announced a partnership with Bristol Myers Squibb and Tempus AI to harness artificial intelligence in the development of treatments for Alzheimer's disease and other neurological disorders. The collaboration comes with a $237m Series E funding round led by Bristol Myers Squibb, valuing the New York-based company at approximately $3bn. The transaction aims to strengthen Pathos AI's research capabilities and accelerate the identification of new therapeutic avenues through the analysis of large-scale medical data. Nicolas Thomas Published on 10/23/2026 at 10:57 am EDT Under the agreement, Tempus AI will build a database covering several hundred thousand patients with neurological diseases, which Pathos AI will be able to access for five years in exchange for $55m. The information will be analyzed by its Pathos Foundry platform to gain a better understanding of the biological mechanisms behind diseases, identify potential treatments and improve the design of clinical trials. Bristol Myers Squibb will receive strategic, nonexclusive access to the technology across all of its research and development activities, as well as exclusive rights for three years to its neuroscience programs. The $237m raised will also enable Pathos AI to develop its platform and advance its pipeline of experimental drugs. The projects involved include JSKN016, an experimental cancer treatment, as...",
    "summary": "Tempus AI signed a $55 million agreement with Pathos AI to provide five-year access to a neurological disease patient database.",
    "planning": false,
    "image_url": "https://cdn.zonebourse.com/static/resize/0/0//images//reuters/2025-05-09T134821Z_1_LYNXMPEL480K7_RTROPTP_4_HEALTH-EU.JPG",
    "confidence": 0.9,
    "published_at": "2026-10-23T14:57:21Z",
    "article_sentence": "Under the agreement, Tempus AI will build a database covering several hundred thousand patients with neurological diseases, which Pathos AI will be able to access for five years in exchange for $55m.",
    "related_company_name": "Pathos AI",
    "related_company_domain": "pathos.ai"
  }
}

curl https://signals.autobound.ai/v1/signals/9ba868b5-873e-95c3-366b-9bb969081daf \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"tempus.com","limit":20}'